GSK
Pharma companies look to Apple’s ResearchKit for R&D
July 13, 2015Medical Communications Apple, GSK, Purdue Pharma, R&D, clinical trials, digital health, iOS, iphone, patient engagement, researchkit
Pharma companies are moving into a new area in drug R&D, by using Apple’s ResearchKit platform to gather data from …
Pfizer acquires meningitis vaccines from GSK
June 23, 2015Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, Pfizer, meningitis
Pharma giants GSK and Pfizer have announced an agreement to transfer the ownership of two meningitis vaccines from GlaxoSmithKline to …
GSK ploughs $95m into research institute
June 17, 2015Research and Development, Sales and Marketing GSK, Pfizer, acquisition, altius, merger, takeover
GlaxoSmithKline is pouring $95 million into a new US research institute to investigate how a cell’s operating system works in …
GSK investigator freed from Chinese prison
June 10, 2015Medical Communications, Sales and Marketing China, GSK, GlaxoSmithKline, brett wells, bribery, scandal
British private investigator Peter Humphrey who worked for GlaxoSmithKline has been released from a Chinese jail following his conviction last …
Perrigo buys OTC products from GSK
June 3, 2015Sales and Marketing GSK, GlaxoSmithKline, Mylan, Perrigo, Teva, brett wells
In an all-cash move with no financial details disclosed Perrigo is buying a portfolio of leading over-the-counter products from GlaxoSmithKline. …
Former GSK Oncology president joins Kesios
June 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Paolo Paoletti, kesios
The Imperial Innovations Group has confirmed the appointment of Dr Paolo Paoletti to be the executive chairman of Kesios Therapeutics.Paoletti …
Another Chinese health official arrested for corruption
May 27, 2015Medical Communications, Sales and Marketing China, GSK, bribery, huang fenping, wang yu
A Chinese health official has been arrested on accusations of bribery as the country continues to crack down on corruption …
Novartis reveals ASCO plans
May 27, 2015Sales and Marketing ASCO, GSK, Novartis
Novartis’ first ASCO conference since buying GlaxoSmithKline’s oncology business will be showcasing drugs from the acquisition. The two firms swapped …
GSK head joins Nabriva as chief medical officer
May 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Elyse Seltzer, GSK, Nabriva Therapeutics
Austrian-based clinical stage biopharma firm Nabriva Therapeutics has appointed Dr Elyse Seltzer as its chief medical officer. Seltzer assumes the role …
Analysts predict Pfizer to swallow GSK
May 21, 2015Sales and Marketing AZ, GSK, GlaxoSmithKline, Pfizer, merger
GlaxoSmithKline has been suggested as a potential M&A target for Pfizer, despite the US company backing out of a similar …
GSK launches new HIV research centre
May 11, 2015Research and Development, Sales and Marketing AIDS, GSK, HIV, UNC-Chapel Hill, ViiV, qura
GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …
Reputation gains from focussing on the patient
May 11, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HIV, Manuel Goncalves, Pfizer, ViiV
Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …
Boardroom shuffles at GSK and Roche
May 8, 2015Medical Communications, Sales and Marketing GSK, Novartis, Roche, ViiV, changes, leadership
GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …
Generics continue to erode GSK sales
May 6, 2015Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory
GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …
GSK files ultra-rare disease application with EMA
May 6, 2015Research and Development, Sales and Marketing EMA, GSK, GSK2696273, Wiskott-Aldrich syndrome, bubble boy, metachromatic leukodystrophy
GlaxoSmithKline has become the first big pharma firm to file for a European marketing authorisation for a gene therapy to …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
